Radiotherapy for localized rectal cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Deutsch, E ^a   Ezra, P ^a   Mangoni, M ^b   Ducreux, M ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Department of Clinical Physiopatology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; SEMUSTINE; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; PLATINUM COMPLEX; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; BOLUS INJECTION; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; HUMAN; INTESTINE OBSTRUCTION; LEUKOPENIA; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECTUM CANCER; RECTUM SURGERY; RECURRENCE RISK; RISK REDUCTION; TREATMENT INDICATION; TREATMENT RESPONSE; COMPUTER ASSISTED RADIOTHERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG THERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; RECTUM; RECTUM TUMOR; REVIEW; SURVIVAL; TREATMENT OUTCOME; VASCULARIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECTAL NEOPLASMS; RECTUM; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36048932368     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm304     Document Type: Conference Paper

References (42)

1. Roels S, Duthoy W, Haustermans K et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1129-1142.
2. Improved survival with preoperative radiotherapy in resectable rectal cancer Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980-987.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-646.
4. Marijnen CA, Kapiteijn E, van de, Velde CJ et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2002; 20: 817-825.
5. Birgisson H, Pahlman L, Gunnarsson U et al. Adverse effects of preoperative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23: 8697-8705.
6. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
7. Holm T, Rutqvist LE, Johansson H et al. Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: Causes and risk factors. Br J Surg 1996; 83: 964-968.
8. Camma C, Giunta M, Fiorica F et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 2000; 284: 1008-1015.
9. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223.
10. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985; 312: 1465-1472.
11. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 1988; 80: 21-29.
12. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715.
13. O'Connell MJ, Martenson JA, Wieand HS et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507.
14. Wolmark N, Wieand HS, Hyams DM et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000; 92: 388-396.
15. Minsky BD, Cohen AM, Kemeny N et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10: 79-84.
16. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
17. Allal AS, Bieri S, Pelloni A et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: Feasibility, oncologic results and quality of life outcomes. Br J Cancer 2000; 82: 1131-1137.
18. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
19. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
20. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-2953.
21. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-297.
22. Machiels JP, Sempoux C, Scalliet P et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007; 18: 738-744.
23. Kim DY, Jung KH, Kim TH et al. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2007; 67: 378-384.
24. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25: 23-31.
25. Louvet C, de Gramont A, Bennamoun M et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: A 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1992; 28: 611-612.
26. McMullen KP, Blackstock AW. Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer 2002; 2: 24-30.
27. Gerard JP, Chapet O, Nemoz C et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 2003; 21: 1119-1124.
28. Aschele C, Friso ML, Pucciarelli S et al. A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140-1146.
29. Rodel C, Grabenbauer GG, Papadopoulos T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
30. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006; 24: 668-674.
31. Mohiuddin M, Hayne M, Regine WF et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 2000; 48: 1075-1080.
32. Kaminsky-Forrett MC, Conroy T, Luporsi E et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. Int J Radiat Oncol Biol Phys 1998; 42: 935-941.
33. Valentini V, Coco C, Picciocchi A et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002; 53: 664-674.
34. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-8696.
35. Navarro M, Dotor E, Rivera F et al. A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 201-205.
36. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23: 1350-1357.
37. Voelter V, Zouhair A, Vuilleumier H et al. CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: Results from a phase II. Br J Cancer 2006; 95: 710-716.
38. Klautke G, Kuchenmeister U, Foitzik T et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: Results from a phase I/II study. Br J Cancer 2006; 94: 976-981.
39. Mohiuddin M, Winter K, Mitchell E et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650-655.
40. Czito BG, Willett CG, Bendell JC et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J Clin Oncol 2006; 24: 656-662.
41. Rau B, Sturm I, Lage H et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003; 21: 3391-3401.
42. Ghadimi BM, Grade M, Difilippantonio MJ et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005; 23: 1826-1838.